meta_pixel
Tapesearch Logo
Log in
Plenary Session

5.08 - LaceWing RCT Phase 3 Blood - Spin Cycle

Plenary Session

Vinay Prasad, MD MPH

Health, Medicine, Policy, Oncology, Science & Medicine

4.7789 Ratings

🗓️ 18 August 2022

⏱️ 34 minutes

🧾️ Download transcript

Summary

VP discusses the LaceWing study in Blood. A Phase 3 RCT of GILT AZA vs AZA; Medical writers; confounding; table 1; balance; and so much more

Transcript

Click on a timestamp to play from that location

0:00.0

Welcome back to Plenary Session.

0:02.1

Plenary Session, the podcast at the intersection of medicine,

0:04.4

Oncology, and health policy.

0:06.3

We're back to our roots today.

0:07.9

We got an oncology paper to discuss.

0:09.6

This is by recommendation from a planner to fan of the show.

0:13.0

I saw recently in one of my videos in the many, many, many, many, many comments.

0:17.4

Somebody wrote, we need more oncology content on this channel.

0:20.4

And I thought to myself,

0:21.6

you one person are right. Forget about what everyone else thinks. You're right. And we're

0:27.1

going to get there. This is a tip-off by a listener of plenary session. Someone I know who says,

0:33.3

quote, I'm no expert. But when I read this, I thought, you probably want to talk about this.

0:38.1

This has got some issues to talk about.

0:40.0

This is the lace wing study.

0:41.7

The phase three trial of giltrinin plus azicidine versus azicidine alone,

0:45.1

a newly diagnosed flip-three mutation positive AML inel eligible for intensive chemotherapy.

0:49.3

We all know that the role of the DNA-methal transfraise inhibitors, these non-specific epigenetic

0:55.8

drugs like Asa-Sidididine, has been well established in AML, unfit for intensive chemotherapy

1:00.9

for quite some time with a small but real overall survival benefit against lesser standards

1:06.4

of care. We also know that Aza-Ven has improved upon that in a trial called Viali.

1:12.6

We know that there have been some other kind of shady business going on, such as Agile, where they go Ivo Cidina Baza versus Aza,

1:17.6

even though they probably should have been going against Aza Ven, because a huge chunk of the recruitment time was when you knew that Aza Ven was better,

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from Vinay Prasad, MD MPH, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Vinay Prasad, MD MPH and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2025.